CO6440534A2 - Composiciones y métodos para terapia prolongada con aminopiridinas - Google Patents
Composiciones y métodos para terapia prolongada con aminopiridinasInfo
- Publication number
- CO6440534A2 CO6440534A2 CO11116663A CO11116663A CO6440534A2 CO 6440534 A2 CO6440534 A2 CO 6440534A2 CO 11116663 A CO11116663 A CO 11116663A CO 11116663 A CO11116663 A CO 11116663A CO 6440534 A2 CO6440534 A2 CO 6440534A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- compositions
- aminopiridins
- prolonged therapy
- prolonged
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002035 prolonged effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- -1 4-aminopyridine Chemical class 0.000 abstract 1
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 abstract 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 150000003927 aminopyridines Chemical class 0.000 abstract 1
- 229960004979 fampridine Drugs 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15167909P | 2009-02-11 | 2009-02-11 | |
| US25956309P | 2009-11-09 | 2009-11-09 | |
| US28587209P | 2009-12-11 | 2009-12-11 | |
| US28895309P | 2009-12-22 | 2009-12-22 | |
| US29925910P | 2010-01-28 | 2010-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6440534A2 true CO6440534A2 (es) | 2012-05-15 |
Family
ID=42562065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11116663A CO6440534A2 (es) | 2009-02-11 | 2011-09-09 | Composiciones y métodos para terapia prolongada con aminopiridinas |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20120029035A1 (OSRAM) |
| JP (1) | JP2012517449A (OSRAM) |
| KR (3) | KR20170034452A (OSRAM) |
| CN (2) | CN101896182A (OSRAM) |
| AR (1) | AR075413A1 (OSRAM) |
| AU (2) | AU2010213663A1 (OSRAM) |
| BR (2) | BRPI1000031A2 (OSRAM) |
| CA (1) | CA2751581A1 (OSRAM) |
| CL (1) | CL2011001927A1 (OSRAM) |
| CO (1) | CO6440534A2 (OSRAM) |
| EA (1) | EA022755B1 (OSRAM) |
| EC (1) | ECSP11011311A (OSRAM) |
| IL (1) | IL214500A0 (OSRAM) |
| MX (1) | MX2011008485A (OSRAM) |
| NI (1) | NI201100155A (OSRAM) |
| NZ (1) | NZ595046A (OSRAM) |
| PE (1) | PE20120791A1 (OSRAM) |
| SG (2) | SG173641A1 (OSRAM) |
| TN (1) | TN2011000403A1 (OSRAM) |
| TW (2) | TW201032809A (OSRAM) |
| UY (2) | UY32444A (OSRAM) |
| WO (2) | WO2010093839A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8007826B2 (en) | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
| US20150111930A1 (en) * | 2013-10-23 | 2015-04-23 | Afgin Pharma, Llc | Topical regional neuro-affective therapy |
| TW201125562A (en) * | 2009-09-04 | 2011-08-01 | Acorda Therapeutics Inc | Sustained release fampridine treatment in patients with multiple sclerosis |
| CN102442942A (zh) * | 2010-10-08 | 2012-05-09 | 天津和美生物技术有限公司 | 4-氨基吡啶的多晶型物及其制备和应用 |
| EP2667869A1 (en) * | 2011-01-28 | 2013-12-04 | Acorda Therapeutics, Inc. | Use of potassium channel blockers to treat cerebral palsy |
| EP2814492A1 (en) * | 2012-02-13 | 2014-12-24 | Acorda Therapeutics, Inc. | Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine |
| WO2014028387A1 (en) * | 2012-08-13 | 2014-02-20 | Acorda Therapeutics, Inc. | Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine |
| WO2015118529A1 (en) * | 2014-02-04 | 2015-08-13 | Optimata Ltd. | Method and system for prediction of medical treatment effect |
| RU2580837C1 (ru) * | 2015-05-05 | 2016-04-10 | Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" | Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе |
| US10172842B2 (en) | 2015-09-11 | 2019-01-08 | PharmaDax Inc. | Sustained release oral dosage form containing dalfampridine |
| WO2022124946A1 (ru) * | 2020-12-10 | 2022-06-16 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Новые полиморфные формы 4-аминопиридина и их фармацевтическое применение |
| CN112914884B (zh) * | 2021-01-19 | 2022-02-11 | 重庆火后草科技有限公司 | 通过稳态时长置信度测量睡眠状态下的体重值的方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
| US6288026B1 (en) * | 1999-02-24 | 2001-09-11 | Heinrich Exner | Process and composition for treating diseases with an oil-in-water emulsion |
| US8007826B2 (en) * | 2003-12-11 | 2011-08-30 | Acorda Therapeutics, Inc. | Sustained release aminopyridine composition |
| US8354437B2 (en) * | 2004-04-09 | 2013-01-15 | Acorda Therapeutics, Inc. | Method of using sustained release aminopyridine compositions |
-
2010
- 2010-02-11 WO PCT/US2010/023970 patent/WO2010093839A1/en not_active Ceased
- 2010-02-11 TW TW099104401A patent/TW201032809A/zh unknown
- 2010-02-11 KR KR1020177007639A patent/KR20170034452A/ko not_active Ceased
- 2010-02-11 CN CN2010800008624A patent/CN101896182A/zh active Pending
- 2010-02-11 KR KR1020187029188A patent/KR20180114250A/ko not_active Ceased
- 2010-02-11 US US13/148,231 patent/US20120029035A1/en not_active Abandoned
- 2010-02-11 CA CA2751581A patent/CA2751581A1/en not_active Abandoned
- 2010-02-11 CN CN201080000861XA patent/CN102046174A/zh active Pending
- 2010-02-11 MX MX2011008485A patent/MX2011008485A/es not_active Application Discontinuation
- 2010-02-11 UY UY0001032444A patent/UY32444A/es not_active Application Discontinuation
- 2010-02-11 BR BRPI1000031A patent/BRPI1000031A2/pt not_active Application Discontinuation
- 2010-02-11 KR KR1020117021266A patent/KR20120000560A/ko not_active Ceased
- 2010-02-11 NZ NZ595046A patent/NZ595046A/xx not_active IP Right Cessation
- 2010-02-11 AU AU2010213663A patent/AU2010213663A1/en not_active Abandoned
- 2010-02-11 SG SG2011057783A patent/SG173641A1/en unknown
- 2010-02-11 UY UY0001032445A patent/UY32445A/es not_active Application Discontinuation
- 2010-02-11 WO PCT/US2010/023969 patent/WO2010093838A1/en not_active Ceased
- 2010-02-11 EA EA201171043A patent/EA022755B1/ru unknown
- 2010-02-11 PE PE2011001475A patent/PE20120791A1/es not_active Application Discontinuation
- 2010-02-11 JP JP2011549357A patent/JP2012517449A/ja active Pending
- 2010-02-11 SG SG10201609184PA patent/SG10201609184PA/en unknown
- 2010-02-11 TW TW099104403A patent/TW201034665A/zh unknown
- 2010-02-11 BR BRPI1000030A patent/BRPI1000030A2/pt not_active IP Right Cessation
- 2010-02-12 AR ARP100100402A patent/AR075413A1/es unknown
-
2011
- 2011-08-07 IL IL214500A patent/IL214500A0/en unknown
- 2011-08-09 NI NI201100155A patent/NI201100155A/es unknown
- 2011-08-10 TN TN2011000403A patent/TN2011000403A1/fr unknown
- 2011-08-10 CL CL2011001927A patent/CL2011001927A1/es unknown
- 2011-09-08 EC EC2011011311A patent/ECSP11011311A/es unknown
- 2011-09-09 CO CO11116663A patent/CO6440534A2/es not_active Application Discontinuation
-
2014
- 2014-11-26 US US14/555,487 patent/US20150313886A1/en not_active Abandoned
-
2016
- 2016-08-25 AU AU2016219650A patent/AU2016219650C1/en not_active Ceased
-
2017
- 2017-05-17 US US15/597,991 patent/US20170319562A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6440534A2 (es) | Composiciones y métodos para terapia prolongada con aminopiridinas | |
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| CL2015001731A1 (es) | Compuestos inhibidores de autotaxina; composicion y combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como fibrosis, prurito, cancer, entre otras. | |
| UY34220A (es) | Indazoles, composiciones farmacéuticas y uso de los mismos | |
| UA109464C2 (uk) | Спірооксіндольні антагоністи mdm2 | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2014000517A1 (es) | Compuestos derivados de heterociclos nitrogenados condensados, moduladores de pi3k; composicion farmaceutica; y uso en el tratamiento de una enfermedad tal como asma, lupus, osteoartritis, esclerosis multiple, cancer, entre otras. | |
| PL3321355T3 (pl) | Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne | |
| CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
| PH12013501707A1 (en) | Mesogen-containing compounds | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| IN2015DN01119A (OSRAM) | ||
| ECSP18010481A (es) | Composiciones de plinabulina | |
| IN2014DN06104A (OSRAM) | ||
| CL2014002386A1 (es) | Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras. | |
| CL2016000008A1 (es) | Tratamiento de lesiones inflamatorias de rosacea con ivermectina. | |
| PH12015502118A1 (en) | Pyridin-4-yl derivatives | |
| IN2014DN03298A (OSRAM) | ||
| AR078323A1 (es) | Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple | |
| CO6761366A2 (es) | Composiciones farmacéuticas para el tratamiento de glioma maligno | |
| GT201400042A (es) | Compuesto de benzotiazolona | |
| CL2013001445A1 (es) | Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer. | |
| AR088764A1 (es) | Metodos para el tratamiento de un impedimento sensorial-motriz relacionado con el accidente cerebrovascular con el uso de aminopiridinas | |
| ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia | |
| MX2014008390A (es) | Formulaciones de romidepsina y sus usos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |